PURSUANT TO RULE 13a - 16 OR 15d - 16 OF


For the month of January , 2006


SkyePharma PLC

(Translation of registrant's name into English)


SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X      Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes         No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______


For Immediate Release                                                                                          20 January 2006

                                              SkyePharma Responds to Call for EGM

LONDON,  UK, 20 January 2006 -- SkyePharma PLC (LSE: SKP;  Nasdaq:  SKYE) notes with  disappointment  the press release issued today by
North Atlantic Value LLP and two other  institutional  investors  ("the NAV syndicate")  that they intend to call for an  Extraordinary
General  meeting  ("EGM") to propose the removal of Ian  Gowrie-Smith as a director of SkyePharma and his replacement by a candidate of
their own.

While the Board's  evaluation  and  Strategic  Review are still  ongoing,  the Board is of the opinion that it is premature for the NAV
syndicate,  which  represents  a little  over 13 per cent of the  Company's  issued  share  capital,  to call an EGM for the purpose of
proposing a single  candidate to join the Board.  Furthermore the continuing  media  speculation  while these processes are continuing,
which is likely to be exacerbated by the call for an EGM, is damaging to the company's business and to the interests of shareholders.

For further information please contact:
SkyePharma PLC                                                             +44 207 491 1777
Michael Ashton, Chief Executive Officer
Peter Laing, Director of Corporate Communications                          +44 207 491 5124

Sandra Haughton, US Investor Relations                                      +1 212 753 5780

Buchanan Communications                                                    +44 207 466 5000
Tim Anderson / Mark Court / Rebecca Skye Dietrich

Notes for editors:
About SkyePharma
SkyePharma PLC develops  pharmaceutical  products benefiting from world-leading drug delivery  technologies that provide  easier-to-use
and more effective drug formulations.  There are now eleven approved products incorporating  SkyePharma's  technologies in the areas of
oral,  injectable,  inhaled and topical  delivery,  supported by advanced  solubilisation  capabilities.  For more  information,  visit

Certain statements in this news release are  forward-looking  statements and are made in reliance on the safe harbour provisions of the
U.S. Private Securities  Litigation Act of 1995. Although SkyePharma believes that the expectations  reflected in these forward-looking
statements are reasonable,  it can give no assurance that these expectations will materialize.  Because the expectations are subject to
risks and  uncertainties,  actual results may vary  significantly  from those  expressed or implied by the  forward-looking  statements
based upon a number of factors,  which are described in SkyePharma's  20-F and other documents on file with the SEC. Factors that could
cause differences  between actual results and those implied by the forward-looking  statements  contained in this news release include,
without limitation,  risks related to the development of new products,  risks related to obtaining and maintaining  regulatory approval
for existing,  new or expanded indications of existing and new products,  risks related to SkyePharma's ability to manufacture products
on a large scale or at all, risks related to SkyePharma's  and its marketing  partners'  ability to market products on a large scale to
maintain or expand market share in the face of changes in customer  requirements,  competition and technological  change, risks related
to regulatory  compliance,  the risk of product liability claims, risks related to the ownership and use of intellectual  property, and
risks  related  to  SkyePharma's  ability  to manage  growth.  SkyePharma  undertakes  no  obligation  to  revise  or  update  any such
forward-looking statement to reflect events or circumstances after the date of this release.


     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

                                                                  SkyePharma PLC

                                                                      By: /s/ Douglas Parkhill

                                                                       Name: Douglas Parkhill
                                                                          Title: Company Secretary

Date:   January 20, 2006